At present, no clinical trials have evaluated CAR Ms in hematologic malignancies, while the first in-human phase I trial with the anti-HER2 CAR-M product CT-0508 (NCT04660929) is ongoing in HER2-positive solid tumors. Here, ERBB2 is linked to hematologic disorder.